Advertisement

Tumor Biology

, Volume 35, Issue 8, pp 7513–7521 | Cite as

Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution

  • Wei-gen Zeng
  • Zhi-xiang Zhou
  • Jian-wei Liang
  • Hui-rong Hou
  • Zheng Wang
  • Hai-tao Zhou
  • Xing-mao Zhang
  • Jun-jie Hu
Research Article

Abstract

Desmoid tumors are rare soft tissue tumors with limited data on their management and prognosis. We sought to determine the rates of recurrence after surgery for desmoid tumors and analyze factors predictive of recurrence-free survival (RFS). From February 1976 to October 2011, 233 consecutive patients with desmoid tumors who underwent macroscopically complete resection were included in this study. Clinicopathologic and treatment characteristics were evaluated to determine predictors of recurrence. Patterns of presentation included primary (n = 156, 67.0 %) and locally recurrent (n = 77, 33.0 %) disease initially treated elsewhere. Most patients had a R0 resection (n = 169, 72.5 %). In addition to surgery, 43 (18.5 %) patients received radiotherapy and 10 (4.3 %) patients received systemic therapy. Median follow-up was 54 months; recurrence disease was observed in 62 (26.6 %) patients. The estimated 5- and 10-year RFS was 74.2 % (95 % confidence interval (CI), 68.3–80.1) and 70.7 % (95 % CI, 64.2–77.2), respectively. Factors associated with worse RFS were tumor size larger than 5 cm (hazard ratio (HR) = 3.757; 95 % CI, 1.945–7.259; p < 0.001), extra-abdominal tumor location (abdominal wall referent; HR = 3.373; 95 % CI, 1.425–7.984; p = 0.006), and R1 resection status (HR = 1.901; 95 % CI, 1.140–3.171; p = 0.014). Patients were grouped according to the number of unfavorable prognostic factors; the 10-year RFS rates of patients with zero, one, two, and three prognostic factors were 100, 86.9, 48.5, and 34.4 %, respectively (p < 0.001). Regardless of primary or recurrent disease, surgical resection remains central to the management of patients with desmoid tumors. However, there are clearly different prognostic subgroups that could benefit from different therapeutic strategies, and a wait-and-see policy is a possible option for a subset of patients.

Keywords

Desmoid tumors Prognostic factors Surgery Recurrence Wait-and-see policy 

Notes

Conflict of interest

None.

References

  1. 1.
    Latchford AR, Sturt NJ, Neale K, et al. A 10-year review of surgery for desmoids disease associated with familial adenomatous polyposis. Br J Surg. 2006;93:1258–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Phillips SR, A’Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg. 2004;91:1624–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol. 2012;23(3):562–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Shinagare AB, Ramaiya NH, Jagannathan JP, et al. A to Z of desmoid tumors. AJR Am J Roentgenol. 2011;197(6):W1008–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol. 2009;100:563–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait and see policy according to tumor presentation. J Clin Oncol. 2011;29:3553–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54(10):1229–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17(1):158–67.PubMedGoogle Scholar
  11. 11.
    Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19(13):4028–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19(13):4036–42.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21(7):1390–7.PubMedCrossRefGoogle Scholar
  14. 14.
    van Broekhoven DL, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013;100(9):1214–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40(3):637–45.PubMedCrossRefGoogle Scholar
  16. 16.
    Acker JC, Bossen EH, Halperin EC. The management of desmoids tumors. Int J Radiat Oncol Biol Phys. 1993;26:851–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer. 1993;72:1637–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez R, Kemalyan N, Moseley HS, et al. Problems in diagnosis and management of desmoid tumors. Am J Surg. 1990;159:450–3.PubMedCrossRefGoogle Scholar
  19. 19.
    McKinnon JG, Neifeld JP, Kay S, et al. Management of desmoids tumors. Surg Gynecol Obstet. 1989;169:104–6.PubMedGoogle Scholar
  20. 20.
    Plukker JT, van Oort I, Vermey A, et al. Aggressive fibromatosis(non-familial desmoid tumour): therapeutic problems and the role of adjuvant radiotherapy. Br J Surg. 1995;82:510–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Pritchard DJ, Nascimento AG, Petersen IA. Local control of extraabdominal desmoid tumors. J Bone Joint Surg. 1996;78:848–54.PubMedGoogle Scholar
  22. 22.
    Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoids fibromatosis. Ann Surg. 2013;258(2):347–53.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011;80(3):787–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Micke O, Seegenschmiedt MH. German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2005;61(3):882–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Nuyttens JJ, Rust PF, Thomas Jr CR, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000;88(7):1517–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.PubMedCrossRefGoogle Scholar
  27. 27.
    de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116(9):2258–65.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100(3):612–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Nishida Y, Tsukushi S, Shido Y, et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol. 2010;28:e107–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16:4884–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66(9):1369–74.PubMedGoogle Scholar
  33. 33.
    Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg. 1999;229(6):866–72.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Bonvalot S, Desai A, Coppola S, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23 Suppl 10:x158–66.PubMedCrossRefGoogle Scholar
  35. 35.
    Francis WP, Zippel D, Mack LA, et al. Desmoids: a revelation in biology and treatment. Ann Surg Oncol. 2009;16(6):1650–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Fiore M, Rimareix F, Mariani L, et al. Desmoid-typ fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Molloy AP, Hutchinson B, O'Toole GC. Extra-abdominal desmoid tumours: a review of the literature. Sarcoma. 2012;2012:578052.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Wei-gen Zeng
    • 1
  • Zhi-xiang Zhou
    • 1
  • Jian-wei Liang
    • 1
  • Hui-rong Hou
    • 2
  • Zheng Wang
    • 1
  • Hai-tao Zhou
    • 1
  • Xing-mao Zhang
    • 1
  • Jun-jie Hu
    • 1
  1. 1.Department of Colorectal Surgery, Cancer Hospital, Chinese Academy of Medical SciencesPeking Union Medical CollegeBeijingChina
  2. 2.The Overall Planning Office, Cancer Hospital, Chinese Academy of Medical SciencesPeking Union Medical CollegeBeijingChina

Personalised recommendations